P1.037. Early-Onset Oesophagogastric Adenocarcinoma: Clinicopathological Characteristics and Outcomes From a Ten-Year Tertiary Centre Experience

Clicks: 1
ID: 325680
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #85 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract Topic Esophageal Cancer: Molecular Biology/Pathology Background The incidence of early-onset oesophago-gastric adenocarcinoma (EO-OGC) is rising worldwide, yet its clinicopathological characteristics and oncological outcomes remain incompletely defined. This study aimed to compare the clinical profile, treatment pathways and outcomes of patients with early-onset disease (≤55 years) and late-onset disease (>55 years) presenting with oesophago-gastric cancer. For example, early-onset gastric cancer is now the second most common early-onset gastrointestinal malignancy after colorectal cancer, underscoring the broader rise in cancer among young adults. Understanding how EO-OGC presents and behaves compared with late-onset disease is therefore increasingly important. Methods We conducted a retrospective cohort study at a UK tertiary oesophago-gastric cancer centre, identifying all patients diagnosed with oesophageal, gastro-oesophageal junction, or gastric adenocarcinoma between 2014 and 2025. Patients were stratified into early-onset (≤55 years) and late-onset (>55 years) groups. Clinicopathological data, treatment pathways, postoperative outcomes, and oncological outcomes were extracted from electronic health records. Only patients undergoing curative-intent resection were included in surgical outcome and survival analyses. Siewert type I–II tumours were classified as oesophageal and type III as gastric. Primary outcomes were disease-free survival (DFS) and overall survival (OS). Secondary outcomes included anastomotic leak, hospital-acquired pneumonia, and length of stay. Stage at diagnosis, histology, recurrence pattern, and resection margin status were also compared. Categorical variables were analysed using Chi-square or Fisher’s exact tests; continuous variables using t-tests or Wilcoxon rank-sum tests. Survival was estimated using Kaplan–Meier analysis and compared using log-rank testing. Results Among 960 patients, 162 (16.9%) had early-onset (EO) disease: 75 (46.3%) underwent curative-intent resection compared with 469/798 late-onset (LO) patients (59.4%, p = 0.004). EO patients had significantly fewer comorbidities (18.7% vs 46.3%, p < 0.00001), were more frequently female (30.9% vs 19.0%, p = 0.00014), and presented with advanced stage (p = 0.018). Diffuse gastric histology predominated in EO (65.5% vs 43.9%). EO oesophageal patients had shorter ICU stays (6.5 vs 9.4 days, p = 0.0015) and EO gastric patients had lower pneumonia rates (10.7% vs 40.3%, p = 0.00084). Despite similar postoperative stage, EO patients demonstrated significantly inferior DFS (gastric p = 0.0033; oesophageal p = 0.026), while OS did not differ. Recurrence patterns differed significantly (p = 0.00028): EO gastric cancers showed a higher rate of peritoneal spread (50.0% vs 26.3%), whereas EO oesophageal cancers recurred predominantly in solid organs (56.3% vs 66.7% in LO). Conclusion Early-onset oesophagogastric cancer is an emerging clinical entity that challenges assumptions about cancer in younger adults. Despite comparable perioperative care, these patients experience inferior disease-free survival, driven by advanced stage at presentation and intrinsically aggressive tumour biology. The predominance of diffuse and signet-ring histology, female preponderance and peritoneal recurrence patterns highlights a phenotype distinct from late-onset disease. Improving outcomes will require earlier recognition, routine biomarker testing and molecular risk stratification. Large-scale genomic and epidemiological studies are essential to clarify disease origins. Without such advances, early-onset patients will remain under-recognised and fail to realise any survival advantage youth might otherwise confer.
Reference Key
openalex_W7203909411 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Unaiza Waheed, A. L. Burn, Alexander Ribbits, Mohammad Jamal Faisal, Vijayendran Sujendran, Andrew Hindmarsh, Kiran Purushothaman, Ayesha Noorani
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.185
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.